Literature DB >> 31263960

Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension.

Stéphanie Saxer1,2, Mona Lichtblau1, Charlotte Berlier1, Elisabeth D Hasler1, Esther I Schwarz1, Silvia Ulrich3.   

Abstract

INTRODUCTION: The cardinal symptom of pulmonary hypertension (PH) is dyspnea on exertion, leading to decreased activity in daily living. The aim of this study was to analyze daily physical activity in incident patients with arterial or chronic thromboembolic PH (PAH/CTEPH) and to investigate its correlation with pulmonary hemodynamics, symptoms, exercise capacity, and other outcomes.
METHODS: Incident patients with PAH/CTEPH had a 1-week activity assessment by the arm-worn accelerometer SenseWear within - 3 months/+ 2 weeks of the diagnostic right heart catheterization (RHC) and baseline assessments including 6-minute walking distance (6MWD). Activity was correlated to RHC data at rest and exercise and to other outcomes.
RESULTS: Thirty-nine PH-patients (24 PAH, 15 CTEPH, 23 females, 65(54;73) years, mean pulmonary artery pressure (mPAP) 38(30;46) mmHg, cardiac output (CO) 5.2(4.6;6.3) l/min, 6MWD 458(300;593) m) were included. 64% had a sedentary lifestyle ( < 5000 steps/day), 26% were moderately active (5000-9999 steps/day), and 10% were active. In a multivariate stepwise regression analysis including age, gender, 6MWD and hemodynamics at rest and during exercise (heart rate, mPAP, stroke volume), the 6MWD was the only independent predictor of steps/day (B = 16.8 (95% CI 11.6-22.0), p < 0.001).
CONCLUSION: Daily physical activity as steps/day assessed in incident patients with PAH/CTEPH did not well correlate with invasive hemodynamics at rest or during exercise, but very well with the 6MWD. Whether daily activity assessments provide additional information to simple walk distance on risk factor profiles during follow-up in patients with PAH/CTEPH remains to be clarified.

Entities:  

Keywords:  Actigraphy; Exercise; Hemodynamics; Physical activity; Pulmonary arterial hypertension; Pulmonary hypertension

Mesh:

Year:  2019        PMID: 31263960     DOI: 10.1007/s00408-019-00248-x

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  25 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Variability in physical activity patterns as measured by the SenseWear Armband: how many days are needed?

Authors:  Tineke Scheers; Renaat Philippaerts; Johan Lefevre
Journal:  Eur J Appl Physiol       Date:  2011-08-28       Impact factor: 3.078

3.  Physical Activity and Fatigue in Patients with Sarcoidosis.

Authors:  Thomas Bahmer; Henrik Watz; Maria Develaska; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Anne-Marie Kirsten
Journal:  Respiration       Date:  2017-11-09       Impact factor: 3.580

4.  Physical Activity and Symptoms in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Haochang Shou; Jason S Fritz; K Akaya Smith; Anjali Vaidya; Diane Pinder; Christine Archer-Chicko; Danielle Dubow; Harold I Palevsky; Marilyn S Sommers; Steven M Kawut
Journal:  Chest       Date:  2016-02-15       Impact factor: 9.410

5.  Pressure-Flow During Exercise Catheterization Predicts Survival in Pulmonary Hypertension.

Authors:  Elisabeth D Hasler; Séverine Müller-Mottet; Michael Furian; Stéphanie Saxer; Lars C Huber; Marco Maggiorini; Rudolf Speich; Konrad E Bloch; Silvia Ulrich
Journal:  Chest       Date:  2016-02-15       Impact factor: 9.410

6.  Respiratory muscle strength in patients with pulmonary hypertension: The relationship with exercise capacity, physical activity level, and quality of life.

Authors:  Goksen Kuran Aslan; Buket Akinci; Ipek Yeldan; Gulfer Okumus
Journal:  Clin Respir J       Date:  2016-12-09       Impact factor: 2.570

7.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

8.  Assessment of daily life physical activities in pulmonary arterial hypertension.

Authors:  Vincent Mainguy; Steeve Provencher; François Maltais; Simon Malenfant; Didier Saey
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

9.  Chronic thromboembolic pulmonary hypertension.

Authors:  Nick H Kim; Marion Delcroix; Xavier Jais; Michael M Madani; Hiromi Matsubara; Eckhard Mayer; Takeshi Ogo; Victor F Tapson; Hossein-Ardeschir Ghofrani; David P Jenkins
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

10.  Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry.

Authors:  Hans Van Remoortel; Yogini Raste; Zafeiris Louvaris; Santiago Giavedoni; Chris Burtin; Daniel Langer; Frederick Wilson; Roberto Rabinovich; Ioannis Vogiatzis; Nicholas S Hopkinson; Thierry Troosters
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more
  3 in total

1.  Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.

Authors:  Miaofa Ying; Jin Song; Shenglong Gu; Rui Zhao; Mingxing Li
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

Review 2.  Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop.

Authors:  Jane A Leopold; Steven M Kawut; Micheala A Aldred; Stephen L Archer; Ray L Benza; Michael R Bristow; Evan L Brittain; Naomi Chesler; Frances S DeMan; Serpil C Erzurum; Mark T Gladwin; Paul M Hassoun; Anna R Hemnes; Tim Lahm; Joao A C Lima; Joseph Loscalzo; Bradley A Maron; Laura Mercer Rosa; John H Newman; Susan Redline; Stuart Rich; Franz Rischard; Lissa Sugeng; W H Wilson Tang; Ryan J Tedford; Emily J Tsai; Corey E Ventetuolo; YouYang Zhou; Neil R Aggarwal; Lei Xiao
Journal:  Circ Heart Fail       Date:  2021-06-15       Impact factor: 10.447

3.  Physical Activity in Pulmonary Arterial Hypertension during Pandemic COVID-19 and the Potential Impact of Mental Factors.

Authors:  Maria Wieteska-Miłek; Sebastian Szmit; Michał Florczyk; Anna Witowicz; Marcin Kurzyna
Journal:  Int J Environ Res Public Health       Date:  2022-07-08       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.